Govt issues revised guidelines on use of drugs in Covid patients

It warned against the use of the drug for patients who are not on oxygen support or in home settings.

437
Guidelines
Guidelines

Last Updated on January 9, 2024 by The Health Master

According to the revised “Clinical Guidance for Management of Adult COVID-19 Patients”, there is no evidence of injectable steroids benefitting COVID patients not requiring oxygen supplementation or continuing after discharge, according to the revised ‘Clinical Guidance for Management of Adult COVID-19 Patients’.

Revised guidelines: The revised guidelines issued by AIIMSICMR-COVID-19 National Task Force and Joint Monitoring Group (DGHS) under the Union health ministry also stated that anti-inflammatory or immunomodulatory therapy, such as steroids, can have the risk of secondary infection like invasive mucormycosis, when used too early, at higher dose or for longer than required.

Methylprednisolone injection: Injection methylprednisolone of 0.5 to one mg/kg in two divided doses, or an equivalent dose of dexamethasone, can be given usually for a duration of five to 10 days in moderate cases, the guidelines stated. In severe cases, the same drug in two divided doses of one to two mg/kg can be given for the same duration.

Budesonide: “Inhalational budesonide (given via metered dose inhaler/dry powder inhaler) at a dose of 800 mcg BD for five days can be given in mild cases if symptoms (fever and/or cough) are persistent beyond five days of disease onset,” it was stated in the guidelines.

If cough persists for more than two-three weeks, one should opt for investigation for tuberculosis and other conditions, they stated.

Remdesivir: The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with “moderate to severe” disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.

It warned against the use of the drug for patients who are not on oxygen support or in home settings.

Tocilizumab: According to the guidelines, EUA or off-label use of the tocilizumab drug may be considered for use in the presence of severe disease, preferably within 24 to 48 hours of onset of severe disease or intensive care unit (ICU) admission.

Tocilizumab may be considered for patients with significantly raised inflammatory markers who are not improving despite the use of steroids, with there being no active bacterial, fungal, or tubercular infection, they stated. The guidelines stated that patients affected by coronavirus have been classified into those affected by mild, moderate, and severe disease.

Home isolation: According to the guidance note, upper respiratory tract symptoms without shortness of breath or hypoxia have been classified as mild disease and have been advised to seek home isolation and care.” Those suffering from mild COVID should seek medical attention if they have difficulty in breathing, high grade fever, or severe cough lasting for more than five days.

Oxygen Support: Those having breathlessness with SpO2 fluctuating between 90-93 percent can be admitted to a ward, and they will be considered moderate cases. The guidelines stated that such h patients should be given oxygen support and awake proning should be encouraged in all patients requiring supplemental oxygen therapy, in sequential position changes every two hours, the guidelines stated.

Respiratory rate over 30 per minute, breathlessness or SpO2 lower than 90 per cent on room air should be considered as severe disease and such patients have to admitted to an ICU as they will need respiratory support, they stated.

Such patients should be put on respiratory support. Non-invasive ventilation (NIV) — helmet or face mask interface depending on availability — may be considered in those with increasing oxygen requirements if work of breathing is low.

High flow nasal cannula should be considered in patients with increasing oxygen requirements. Intubation should be prioritised in patients with high work of breathing if NIV is not tolerated and institutional protocol for ventilatory management should be used when required, the new guidelines stated.

Those aged above 60 years, or those having cardiovascular disease, hypertension, and coronary artery disease, diabetes mellitus, and other immunocompromised states, such as HIV, active tuberculosis, chronic lung, kidney, or liver disease, cerebrovascular disease, or obesity, are at high risk for severe disease and mortality, the guidelines stated.

Pharmaceutical Budget 2022: Expectations

NPPA to conduct study on Price Regulatory Policies in these 10 countries

IPC flags safety alert against Covid-19 drug Remdesivir

FDA alerts Medical Officers to maintain healthy Oxygen status

Which medicine works best for Covid-19 treatment? WHO answers

Govt notifies New Drugs and Clinical Trials (Amendment) Rules 2022

Drug recall: Sun Pharma, Lupin recall these drugs

BIS notifies new standard for these Medical Devices

Latest Notifications: Medical Devices

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news